Geneferm Biotechnology Co Stock Earnings Per Share
| 1796 Stock | TWD 49.95 0.45 0.89% |
GeneFerm Biotechnology Co fundamentals help investors to digest information that contributes to GeneFerm Biotechnology's financial success or failures. It also enables traders to predict the movement of GeneFerm Stock. The fundamental analysis module provides a way to measure GeneFerm Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GeneFerm Biotechnology stock.
GeneFerm |
GeneFerm Biotechnology Co Company Earnings Per Share Analysis
GeneFerm Biotechnology's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current GeneFerm Biotechnology Earnings Per Share | 2.18 X |
Most of GeneFerm Biotechnology's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GeneFerm Biotechnology Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, GeneFerm Biotechnology Co has an Earnings Per Share of 2.18 times. This is 73.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all Taiwan stocks is 30.13% higher than that of the company.
GeneFerm Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GeneFerm Biotechnology's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GeneFerm Biotechnology could also be used in its relative valuation, which is a method of valuing GeneFerm Biotechnology by comparing valuation metrics of similar companies.GeneFerm Biotechnology is currently under evaluation in earnings per share category among its peers.
GeneFerm Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0534 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 41.46 M | |||
| Shares Owned By Insiders | 57.17 % | |||
| Price To Earning | 53.28 X | |||
| Price To Book | 2.94 X | |||
| Price To Sales | 4.16 X | |||
| Revenue | 522.33 M | |||
| Gross Profit | 192.65 M | |||
| EBITDA | 123.07 M | |||
| Net Income | 57.41 M | |||
| Cash And Equivalents | 619.1 M | |||
| Cash Per Share | 15.32 X | |||
| Total Debt | 31.25 M | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 1.98 X | |||
| Book Value Per Share | 19.62 X | |||
| Cash Flow From Operations | 112.23 M | |||
| Earnings Per Share | 2.18 X | |||
| Number Of Employees | 12 | |||
| Beta | 0.89 | |||
| Market Capitalization | 3.22 B | |||
| Total Asset | 1.32 B | |||
| Z Score | 61.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.32 B |
About GeneFerm Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GeneFerm Biotechnology Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneFerm Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneFerm Biotechnology Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with GeneFerm Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneFerm Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneFerm Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against GeneFerm Stock
| 0.55 | 6620 | Handa Pharmaceuticals | PairCorr |
| 0.45 | 4114 | Synmosa Biopharma | PairCorr |
| 0.39 | 6785 | Alar Pharmaceuticals | PairCorr |
| 0.32 | 6539 | DV Biomed | PairCorr |
The ability to find closely correlated positions to GeneFerm Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneFerm Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneFerm Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneFerm Biotechnology Co to buy it.
The correlation of GeneFerm Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneFerm Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneFerm Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneFerm Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GeneFerm Stock Analysis
When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.